Multimedia
Confirm mdx (Negative Prostate Biopsy)
Dr. Kearns Confirm mdx + MRI webinar
Learn how Dr. James Kearns consistently uses MRI + Confirm mdx for complete prostate cancer risk assessment.
Dr. Kearns discusses Confirm mdx and shares his own cases.
About Confirm mdx for Prostate Cancer
How Confirm mdx works
Wim Van Criekinge, PhD*, Professor of Computational Genomics and Bioinformatics at Ghent University in Ghent, Belgium, and Chief Scientific Officer for mdxhealth, discusses Confirm mdx, a test for prostate cancer that uses tissue from a negative biopsy.
Adam J. Cole MD, discuss the utility of Confirm mdx for Prostate Cancer
New Genomic Solutions (for Pathologists). The PsychArmor Institute partnered with Dr. Kirk Wojno* to explain how VA pathologists can use Confirm mdx results to provide more insight on a patient’s risk for aggressive prostate cancer.
Genetic Biomarkers You need to Know About
GPS mdx (Positive Prostate Biopsy)
Dr. Winer Webinar: Smarter Decisions, Better Outcomes: The Patient Trifecta Approach
This webinar will help providers identify:
- Understand how to apply GPS in patients with low- and favorable intermediate-risk Prostate Cancer
- Apply the concept of the patient trifecta to guide treatment choices
- Use GPS insights for risk stratification and care planning
Uncovering Hidden Aggression GPS mdx Studies on AP
Join the experts, Dr. Vip Patel, Dr. Marcio Covas-Moschovas, and Dr. Brooks, as they synthesize data from three notable studies establishing the definitive link between the Genomic Prostate Score (GPS), Adverse Pathology (AP), and 20-year patient survival.
Dr. Kearns gives an overview of Genomic Prostate Score and case studies to provide insight on how he uses the test.
How Genomic Prostate Score (GPS) Works
Follow Michael on his patient journey. From diagnosis with low risk localized prostate cancer to shared decision-making for treatment selection, utilizing the GPS test. GPS can help you identify the wolf in sheep’s clothing to ensure the genomic makeup of the cancer is taken into consideration.
Understanding the GPS Basics
In this short 10 minute video, Senior Medical Liaison Ericka Bagi BSN, RN explains the development of the GPS assay and how the test evaluates adverse outcomes to help make treatment decisions for patients with low to high-risk prostate cancer.
In this short 5 minute clip, Dr. Eric A. Klein, MD*, shares the value of Adverse Pathology as an endpoint. Adverse pathology, as defined by Genomic Prostate Score (formerly known as Oncotype Dx GPS), is the only test to predict long-term outcomes, 20+ years after surgery.
Watch this Q&A with Dr. Tamara Lotan and Danai Wells to learn more about the value of Genomic Prostate Score with positive surgical margins at radical prostatectomy in prostate cancer patients.
Andrew G Winer MD, FACS presents Active Surveillance vs Active Intervention
How to Best Diagnose Prostate Cancer
Exo mdx (Elevated PSA)
Preventing Prostate Biopsies: Urine Exosome Innovations with Dr. Johan Skog
Explore the groundbreaking science, clinical implications, and crucial role exosomes play in the ExoDx Prostate Test with Dr. Johan Skog as he interviews with Dr. Geo on this episode of The Dr. Geo Podcast.
Revolutionizing Prostate Cancer Diagnosis: Urine Testing Insights with Dr. David Albala
Join Dr. Geo in his interview with Dr. David Albala, Chief of Urology at Crouse Hospital and an expert in laparoscopic and robotic urological surgery, as they explore the advancements in prostate cancer diagnosis.
An Integrated Biomarker and MRI Risk Assessment Approach to Prostate Cancer Diagnosis
Prostate cancer guidelines seek to optimize diagnosis while minimizing over-diagnosis. This webinar explores integrating biomarkers like ExoDx Prostate Test with MRI imaging for better risk assessment in patients considering biopsy.
New Technologies for Prostate Screening
In this episode of BackTable Urology, Dr. Jose Silva interviews Dr. Ali Kasraeian, a private practice urologic oncologist in Jacksonville, about different techniques and research on prostate cancer screenings.
Prostate Cancer Diagnosis Made Easier: Urine Tests Explained by Dr. Jason Alter
Dr. Geo interviewed Dr. Jason Alter, the Head of Scientific Affairs at Exosome Diagnostics, regarding the effectiveness of urine tests for identifying prostate cancer.
Simple Non-Invasive Urine Test for Prostate Cancer Risk | Part 3 of 3
Part 3 of 3. Dr. Phranq Tamburri, N.M.D., presents on what makes the ExoDx Prostate Test unique as well as why liquid biomarkers are useful.
Simple Non-Invasive Urine Test for Prostate Cancer Risk | Part 2 of 3
Part 2 of 3. Dr. Phranq Tamburri, N.M.D., explains more about PSA (Prostate Specific Antigen) and three factors in assessing prostate cancer.
Simple Non-Invasive Urine Test for Prostate Cancer Risk | Part 1 of 3
Dr. Phranq Tamburri, N.M.D., presents on pandemic-induced changes in prostate cancer screening, the significance of PSA assessment amidst evolving guidelines, and the benefits of analyzing 3 genes in the ExoDx Prostate Test.
Beyond PSA: Utility of a Urine Gene Expression Assay for Early Prostate Cancer Detection
In this webinar, Dr. John Smith and Dr. Albala explore the breakthrough ExoDx™ Prostate Test, a non-invasive risk assessment tool for prostate cancer. They discuss its accuracy and ability to guide treatment decisions, highlighting its potential to revolutionize prostate cancer management.
Smarter Management of Prostate Cancer: The Five W’s of Utilizing a Liquid Biopsy Approach
Join Dr. Kasraeian for this discussion on the “5 W’s” of Liquid Biopsy approaches, including Who, What, Why Where, and When to use liquid biopsy testing to improve management of prostate cancer.
Entering the Chat Room of Cancer Cells – How They Talk and Why We Should Listen
Small exosome packages act as communication vehicles between cells, much like todays Twitter messages and by intercepting this communication we can now listen in on the cells language to detect cancer earlier as well as see how cancer is changing over time.
Detection of MISEV recommended EV Protein-Markers using Automated Western Blotting
In this video, ExosomeDx lead researcher, Lisa Meyer walks us through a newly developed workflow for detecting MISEV recommended extracellular vesicle (EV) protein markers using automated western blotting.
How the ExoDx Prostate Test Impacts Urology Practice in a Real-World Clinical Setting
The study demonstrated that EPI delivered improved patient outcomes over standard of care in a real-world clinical setting that included 72 urologists, 24 sites and more than 1000 patients.
ExoDx™ Prostate Test – A Solution to Address Fear of the Prostate Biopsy Decision
Recent findings from a real-world clinical study underscore how EPI supports clinical decision making and motivate sometimes unwilling patients to proceed to or defer prostate biopsy. In addition, this tool was proven to detect more high-grade prostate cancers over standard of care parameters alone.
ExoDx Prostate Test: Implications for Value-Based Care
Dr. Judd Moul address practical challenges in prostate cancer risk assessment, and speaks on how The ExoDx™ Prostate Test combats these challenges from a clinical perspective.
Beyond PSA: The ExoDx Prostate™ test (EPI) as a Precision Genomic Biomarker
Dr. David M. Albala, Chief of Urology at Crouse Hospital in Syracuse, New York, explores the novel ExoDx Prostate™ and the growing demand for diagnostic tools that provide prognostic information to identify the right patient to undergo biopsy at the right time.
The Power of Exosomes: Diagnostic Applications and Beyond
Learn more about exosomes in our webinar with Dr. Skog, one of the first scientists to discover exosomes. He will provide an overview of exosomes, dynamics and physiology, exosomes as mediators of infectious disease, therapeutics and diagnostics.
Learn About Research and Clinical Applications of Exosome Based Liquid Biopsies
Listen as Dr. Skog breaks down the science behind exosome-based liquid-biopsies and how they can be used to address diagnostic uncertainty in the field of prostate cancer.
Mdxhealth Precision Prostate Cancer Pathway
Dr. Neal Shore* presents a comprehensive overview of mdxhealth’s precision prostate cancer pathway. You will learn how Select mdx, Confirm mdx, and Genomic Prostate Score may help you minimize the challenges you face while identifying and diagnosing patients who are at risk for Prostate Cancer. He reviews how the diagnostics work, validation data, what to expect from a report, and a few case studies.
Dr. Winer* presents mdxhealth’s Prostate Cancer Portfolio Webinar.
Confirm mdx and GPS Assays
Mdxhealth’s Confirm mdx and GPS assays presented by Dr. Scott Sellinger*
Resolve mdx (Urinary Tract Infection)
Resolve mdx is an advanced UTI test that combines the precision of PCR pathogen identification and resistance gene detection with proprietary antibiotic susceptibility testing called ASTX to identify antibiotics best suited to resolve the infection. Results are delivered within 24-48 hours for prompt and accurate pathogen identification and personalized antibiotic recommendations.
*Paid advisor for mdxhealth
